Keros Therapeutics (KROS) said Tuesday that it will receive a $200 million upfront payment from Takeda Pharmaceutical (TAK) in connection to a global development and commercialization license deal to advance elritercept.
The license agreement with Takeda took effect on Jan. 16, the biopharmaceutical company said.
Keros shares were up 5% and Takeda shares were edging 0.3% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。